The Report Includes:
- An introduction to interleukin-2 (IL-2) and identification of its applications
- Insights into the latest trends and technologies in the IL-2 research and development
- Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
- Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zurich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile
- Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off-target effect
- An understanding of various conditions which may develop as an off-target effect in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse-remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)
Table of Contents
Chapter 1 Introduction
- Introduction
- Interleukin-2 an Important Driver for T Cell Homeostasis
- Analyst's Credentials
- Related Reports
Chapter 2 A Balancing Act
- Targeted Effects
- Off-Target Effects
Chapter 3 Approved IL-2 Therapies
- IL-2 Antagonist Immunosuppressant
- Simulet (Basilximab) Novartis
- Zenapax (Daclizumab) Roche
- Zinbryta (Daclizumab) AbbVie/Biogen
- Leukotac (Iolimomab) ElsaLys Biotech
- IL-2 Agonist Cancer Immunotherapy
- Proleukin (Aldesleukin) Novartis/Chiron
Chapter 4 Future Opportunities
- New Strategies to Harness IL-2's Potential
- IL-2 Monoclonal Antibodies
- IL-2 Antibody Drug Conjugates
- IL-2 Antibody?Cytokine Fusion Proteins
- IL-2 Mutant Superkines
- IL-2 Therapeutic Protein Inhibitor
- IL-2 Immunotoxins
- IL-2 Radioimmunoconjugates
- Long-Acting Recombinant IL-2
- IL-2 Based Vaccines
Chapter 5 IL-2 Watch for These Drugs
Chapter 6 References
List of Tables
Table 1: Expression of CD25, CD122 and CD132 in Immune and Nonimmune Cells
Table 2: Selection of Clinical Studies With IL-2 Drugs at Different Doses on Different Targets
Table 3: IL-2 Agents to Watch
List of Figures
Figure 1: IL-2 Signaling Pathways and Their Primary Biological Effects in Different Immune Cell Types
Figure 2: Three Different Types of IL-2 Receptors
Figure 3: Balancing Efficacy and Safety
Figure 4: Drugs Targeting IL-2
Figure 5: Computer Model of Neoleukin-2/15 Structure
Companies Mentioned
- AbbVie
- ADC Therapeutics
- Anaveon AG
- Biogen
- Chiron
- ElsaLys Biotech
- Medicenna
- Nektar Therapeutics
- Novartis
- Roche
- Syncona
- University of Zuirich
